Redefining the value in partnerships ahead of DCAT Week

As the industry emerges from a prolonged funding slowdown, the roundtable highlights cautious optimism. Rather than a broad-based recovery, participants describe a selective, research-driven uptick focused on clinic-ready assets and higher-complexity modalities. Discussions have shifted from speculative experimentation to practical considerations, including manufacturability, timeline efficiency and the ability to scale reliably. This suggests growth that is deliberate, technology selective and weighted toward assets with clearer commercial pathways.

LATEST VIDEO

Latest news

31st March 2026

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

31st March 2026

Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland

31st March 2026

Swiss Rockets Collaborates with Lonza to Advance Torqur’s Oncology Drug Candidate Bimiralisib into Late-Stage Clinical Development

31st March 2026

Symeres and Ambagon Therapeutics collaborate on molecular glue research in colorectal cancer

31st March 2026

Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption

30th March 2026

ImmuneOncia Therapeutics and Lonza Collaborate to Manufacture Danburstotug, a PD-L1 Antibody Targeting Immuno-Oncology

26th March 2026

Lonza Launches Media Development Lab in Singapore for Cell Culture Media Optimization

25th March 2026

Kindeva® commemorates 70 years of the pMDI as inventors are inducted into the ‘National Inventors Hall of Fame’

25th March 2026

Merck braces for Keytruda patent loss with $6.7 billion Terns bet

24th March 2026

OLON ADVANCE GLOBAL EXPANSION AND SUSTAINABLE BIOMANUFACTURING EXPERTISE AT DCAT NEW YORK

24th March 2026

INDENA UNVEILS ENHANCED HPAPI AND TARGETED THERAPY CAPABILITIES AT DCAT WEEK 2026

This week’s featured articles

A woman’s view from the HAS Group

Breaking Barriers: Women Scientists Rising to Leadership in Pharma

Strategic Growth in Biologics Manufacturing: Insights from Lonza's Acquisition of the Vacaville Site

Grifols’ supply chain strategy offers lessons beyond saline

Axplora: Mastering complexity

Partnered with top industry events and organisations